Intelligent Bio Solutions Inc. Announces Leading U.K. Container Haulier Switching to Fingerprint Drug Screening System for In-house Testing
October 31, 2022 09:05 ET
|
Intelligent Bio Solutions
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the "Company”), a life sciences company delivering intelligent, non-invasive, real-time testing solutions,...
GBS Inc. Initiates Company Name Change to Intelligent Bio Solutions Inc. (IBSS) and Announces Key Executive Appointments
October 26, 2022 09:05 ET
|
GBS, Inc.
- Name change to more closely reflect firm’s expanding portfolio of intelligent, efficient, convenient and practical noninvasive and drug testing technologies and products - - Harry Simeonidis...
GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology
October 04, 2022 09:05 ET
|
GBS, Inc.
The transaction further solidifies GBS’ leadership in non-invasive, real-time diagnostic testing with an expanded portfolio and geographical reachGBS’ global footprint includes operations in...
GBS Inc. Reports Fourth Quarter and Full Year ended June 30, 2022 Preliminary Financial Results and Recent Business Highlights
August 31, 2022 16:05 ET
|
GBS, Inc.
- Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquisition - - Completed collection and...
GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31
August 29, 2022 09:05 ET
|
GBS, Inc.
NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners...
GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood
July 13, 2022 09:05 ET
|
GBS, Inc.
The trial is single center, prospective study collecting coincident samples of oral fluids and blood to evaluate the time-course of glucose NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc....
GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia Campus
June 23, 2022 09:05 ET
|
GBS, Inc.
NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners...
GBS INC. Announces Adjournment of 2022 Annual Meeting of Stockholders to July 13, 2022
June 16, 2022 16:30 ET
|
GBS, Inc.
NEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners...
GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse
June 16, 2022 08:32 ET
|
GBS, Inc.
NEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners...
GBS Inc. to Present at the H.C. Wainwright Global Investment Conference
May 16, 2022 16:05 ET
|
GBS, Inc.
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners...